Summit Therapeutics shares are trading higher as investors react to the company’s latest update that multiple ivonescimab data sets from Phase III studies in advanced non-small cell lung cancer (NSCLC) will be featured at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen. The update highlights a notable intracranial progression-free survival (PFS) benefit for ivonescimab plus chemotherapy versus chemotherapy in patients with baseline brain metastases (10.1 months vs 6.5 months; HR 0.53; nominal p=0.0068), helping frame the upcoming medical-meeting readouts as a near-term catalyst. (smmttx.com)

For NSCLC, brain metastases remain a high-impact clinical problem, and an intracranial PFS improvement can influence how physicians and investors view differentiation versus existing immunotherapy regimens. With Summit’s equity story heavily tied to ivonescimab’s Phase III package, incremental signs of efficacy in difficult subpopulations can quickly shift sentiment and drive risk-on positioning into conference data events. (simplywall.st)

Key swing factors for the stock include the tone and depth of the ELCC presentations (including subgroup consistency, safety, and durability) and subsequent updates across the broader HARMONi program. Investors are also focused on 2026 clinical milestones such as additional Phase III readouts and the path to regulatory submissions, since confirmation on harder endpoints like overall survival is typically what solidifies the commercial thesis for a potential new standard of care. (investing.com)

Separately, Summit recently filed a preliminary proxy statement seeking shareholder approval to increase the share reserve under its 2020 Stock Incentive Plan by 8 million shares ahead of a June 10, 2026 virtual meeting (record date April 15, 2026). While not an obvious driver of a single-day rise, it is part of the near-term corporate calendar investors may monitor alongside clinical catalysts. (stocktitan.net)